About
About
Close
About Targovax
Management Team
Board of Directors
Careers
Technology
Technology
Close
ONCOS – Oncolyctic Virus
Intellectual Property Rights
Publications
Pipeline
Pipeline
Close
Our pipeline
Development Program
Melanoma
Mesothelioma
Next generation viruses
Partnering
Investors & Media
Investors & Media
Close
Our strategy
Press releases
Financial Reports
Presentations
Prospectus
Debt
Share information
Share facts
Largest shareholders
Dividend policy
Analyst coverage
Registrar and auditor
Events
Contact
Subscribe
Governance
Governance
Close
Corporate Governance Policy
Corporate Social Responsibility Principles
Remuneration Principles
About General Meeting
General Meetings
Board of Directors
Nomination Committee
Committees
Management
Articles of Association
Contacts
Contacts
Close
Offices
Investors & Media
About
About Targovax
Management Team
Board of Directors
Collaborations
Careers
Technology
ONCOS – Oncolyctic Virus
Intellectual Property Rights
Publications
Pipeline
Our pipeline
Development program
Partnering
TG Mutant RAS neoantigen vaccine – Available for partnering
Investors & Media
Our strategy
Share information
Share facts
Largest shareholders
Dividend policy
Analyst coverage
Registrar and auditor
Financial Reports
Press releases
Presentations
Prospectus
Debt
Events
Subscribe
Contact
Governance
Corporate Governance Report
Corporate Social Responsibility Principles
About General Meeting
General Meetings
Board of Directors
Nomination Committee
Committees
Management
Articles of Association
Contacts
Offices
Investors & Media
Search for:
Press releases
Share price
Share price
All press releases
Press releases - Regulatory
Press releases - Non-regulatory
2011
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
All years
All subjects
Corporate news
Other
November 28, 2011
Press release - Non-regulatory
9 million NOK for development of cancer vaccine
June 13, 2011
Press release - Non-regulatory
Targovax AS received a grant from Innovation Norway
Subscribe
Press releases
Financial reports
Read more about our Protection of your personal data.
